Podcast Summary: The Glenn Beck Program – Best of the Program | Guest: Dr. Jay Bhattacharya | 5/12/25

Host: Blaze Podcast Network
Guest: Dr. Jay Bhattacharya, Director of the National Institutes of Health (NIH)
Release Date: May 12, 2025

1. Introduction

In this "Best of the Glenn Beck Program" episode, hosted by Glenn Beck, Dr. Jay Bhattacharya joins as a special guest to discuss pressing issues in American healthcare, the implications of recent policy changes, advancements in artificial intelligence (AI), and a concerning incident at a high-security biomedical lab.

2. Government Regulation of Prescription Drug Prices

Glenn Beck initiates the discussion by addressing President Trump's executive order aimed at lowering prescription drug costs. He expresses a nuanced position, balancing his free-market ideals with the pragmatic need to address exorbitant drug prices.

Glenn Beck [34:03]: "You have to have competition, accountability and consequences. We don't have any of those things right now. None of those things. That's not a true free market. That's a casino where the house always wins and you and I always lose."

Dr. Jay Bhattacharya provides an expert analysis of the issue, highlighting the stark price disparities between the United States and Europe. He explains that American consumers are paying significantly higher prices for the same drugs available in Europe at a fraction of the cost.

Dr. Jay Bhattacharya [34:20]: "Americans pay some, sometimes between two to five times, sometimes as high as 10 times the price of the same drug as Europeans do. This indicates a very unhealthy market."

He commends the executive order as a "huge move forward," emphasizing the need for global cooperation to ensure fair pricing without stifling research and development (R&D).

3. The Role of AI in Drug Development and Society

Transitioning to technology, Glenn Beck brings up the potential of AI, such as Alphafold, in revolutionizing drug development by reducing costs and accelerating the research process.

Glenn Beck [35:49]: "Doesn't the promise of AI, AGI, ASI lessen this whole thing of we need gobs of money to be able to do R and D because that should, you know, maybe five years from now begin to cut those costs dramatically?"

Dr. Bhattacharya acknowledges the promise of AI in enhancing scientific research but clarifies that while AI can streamline initial drug development stages, expensive clinical trials will still be necessary.

Dr. Jay Bhattacharya [36:20]: "Drug development is always going to be expensive. You still have to run randomized large scale clinical trials and those are going to be expensive."

He remains optimistic that AI will eventually make drug development more efficient, potentially reducing the financial burden associated with bringing new drugs to market.

4. Lab Safety Incident at Fort Detrick

A significant portion of the discussion centers around a disturbing incident at the Fort Detrick NIH lab, where a lab worker sabotaged another’s protective suit, risking exposure to deadly pathogens.

Dr. Jay Bhattacharya [38:02]: "A lab worker had cut a hole in a biocontainment suit of a fellow worker with the express intention of getting that worker infected... I was absolutely livid."

Dr. Bhattacharya details his immediate actions upon learning of the incident, including shutting down the lab operations to ensure safety and secure handling of dangerous pathogens.

Dr. Jay Bhattacharya [40:50]: "I won't reopen the lab until the safety environment is absolutely solid."

He criticizes the previous administration's lax approach to lab safety and emphasizes the necessity of a robust safety culture to prevent future catastrophes.

5. Future of Science and Public Health Policy

Glenn Beck probes further into the implications of such lab incidents and the broader scope of public health policies, questioning whether current approaches may inadvertently increase pandemic risks.

Glenn Beck [43:11]: "Have we stopped all of the gain of function stuff now? Are you convinced it's done?"

Dr. Bhattacharya responds by explaining the recent executive order signed by President Trump to pause all gain-of-function research, outlining the NIH's commitment to developing a framework that involves public input before approving such high-risk studies.

Dr. Jay Bhattacharya [43:17]: "President Trump signed an absolutely historic executive order that puts a full pause on all gain of function work throughout the government."

He advocates for greater public involvement in decision-making processes related to high-risk scientific research to ensure that societal risks are adequately considered.

6. Reflections and Reforms

Towards the end of the conversation, Dr. Bhattacharya reflects on his transition to the NIH, overcoming previous criticisms, and his vision for institutional reform to prioritize public health over unchecked scientific ambitions.

Dr. Jay Bhattacharya [47:15]: "Going forward is reform. How do we change the institution so that it is focused on the health needs of the American people rather than these utopian schemes to end all pandemics without any heed whatsoever to the risk that they take?"

He underscores the importance of balancing scientific advancement with ethical responsibility, ensuring that research serves the genuine health needs of the populace.

7. Conclusion

The episode wraps up with Glenn Beck expressing gratitude to Dr. Bhattacharya for his contributions during the COVID-19 pandemic and his ongoing efforts to steer the NIH towards greater accountability and public-oriented policies.

Glenn Beck [47:35]: "Thank you for standing up so strongly now. And congratulations on being our director of the NIH."

Key Takeaways:

• Prescription Drug Pricing: Efforts to regulate drug prices are critical to ensuring affordability and preventing consumer exploitation. The executive order represents a pivotal step toward addressing systemic pricing disparities.

• AI in Healthcare: AI holds transformative potential for reducing drug development costs and accelerating medical research, though it won't eliminate the need for costly clinical trials.

• Lab Safety: Strict adherence to safety protocols in high-security labs is non-negotiable. Recent incidents highlight the need for robust oversight and accountability to prevent accidental or intentional pathogen releases.

• Public Health Policy Reforms: Aligning scientific research with public health needs requires institutional reforms that emphasize transparency, public involvement, and ethical responsibility.

This episode provides insightful perspectives on the intersection of healthcare policy, technological advancement, and scientific responsibility, offering listeners a comprehensive understanding of the current landscape and future directions in these critical areas.